CBOE

CBOE edges NDAQ on valuation, share performance, growth estimates and analyst sentiment, backed by recurring revenues and diversification.

CBOE (CBOE) possesses solid growth attributes, which could help it handily outperform the market.

CBOE (CBOE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors can find opportunities in stocks where declining share prices are pushing valuations below their historical average.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Derivatives exchange Cboe Global Markets expects to list options on SK Hynix's U.S.-listed shares two business days ​after the stock's trading debut, a source familiar with the matter ‌told Reuters on Friday.

CBOE (CBOE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

LOS ANGELES, July 7, 2026 /PRNewswire/ -- Langar Investment Management LLC, the adviser to the Langar Global HealthTech ETF (NYSE Arca: LGHT), today announced the transfer of the primary listing of LGHT from NYSE Arca to the Cboe BZX Exchange on or about June 29, 2026. Current shareholders of LGHT are not required to take any action, nor is the transfer expected to have any effect on the trading of the Fund's shares.

Cboe Global's revenue growth extends beyond trading, powered by options strength, recurring data services, global expansion and a diversified revenue mix.

Cboe Global's discounted valuation, diversified revenues, higher growth targets and bullish estimates make the stock look compelling.